Reinventing type 2 diabetes: Pathogenesis, treatment, and prevention

JAMA

Volumn 299, Issue 10, 2008, Pages 1185-1187

  Unger, Roger H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

CLINICAL TRIAL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCOGENOLYSIS; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; TREATMENT OUTCOME; ARTICLE; LIPOGENESIS; PATHOPHYSIOLOGY; PHYSIOLOGY;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPOGENESIS;

EID: 40749152739     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.299.10.1185     Document Type: Note

References (21)

1. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology. 2003;144(12):5159-5165.
2. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299(3):316-323.
3. Trends in intake of energy and macronutrients - United States, 1971-2000. MMWR Morb Mortal Wkly Rep. 2004;53(4):80-82.
4. Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance - United States, 2005. MMWR Surveill Summ. 2006;55(5):1-108.
5. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295(13):1549-1555.
6. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest. 1960;39:1157-1175.
7. Merimee TJ. Obesity and hyperinsulinism. N Engl J Med. 1971;285(15):856-857.
8. Sherwin RS, Kramer KJ, Tobin JD, et al. A model of the kinetics of insulin in man. J Clin Invest. 1974;53(5):1481-1492.
9. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173-194.
10. Reaven GM. Insulin secretion and insulin action in non-insulin-dependent diabetes mellitus: which defect is primary? Diabetes Care. 1984;7(suppl 1):17-24.
11. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.
12. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785-789.
13. McGarry JD. What if Minkowski had been ageusic? an alternative angle on diabetes. Science. 1992;258(5083):766-770.
14. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest. 2002;32(suppl 3):14-23.
15. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007;87(2):507-520.
16. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A. 1994;91(23):10878-10882.
17. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell. 2000;6(1):77-86.
18. Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab. 2003;14(9):398-403.
19. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54(3):603-608.
20. For safety, NHLBI changes intensive blood sugar treatment strategy in clinical trial of diabetes and cardiovascular disease [press release]. NIH News, National Heart, Lung, and Blood Institute; February 6, 2008.
21. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50(2):259-267.